N
Nuvalent, Inc. (NUVL)
NMS – Real vaqt narxi. Valyuta: USD
102.54
-2.01 (-1.92%)
Yopilishda: May 12, 2026, 4:00 PM EDT
103.54
+1.00 (0.98%)
Bozor oldidan: May 13, 2026, 6:49 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
102.54
-2.01 (-1.92%)
Yopilishda: May 12, 2026, 4:00 PM EDT
103.54
+1.00 (0.98%)
Bozor oldidan: May 13, 2026, 6:49 AM EDT
Nuvalent, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, saraton bilan kasallangan bemorlar uchun terapiyalarni ishlab chiqish bilan shug'ullanadi. Uning asosiy mahsulot nomzodlari quyidagilardir: Zidesamtinib (NVL-520), ROS1 proto-onkogen 1 (ROS1)-pozitiv kichik hujayrali o'pka rakki (NSCLC) bemorlarida ROS1 tirozin kinaz inhibitorlari (TKI) dan foydalanishni cheklashi mumkin bo'lgan davolanishga chidamlilikning paydo bo'lishi, markaziy asab tizimi (CNS) bilan bog'liq noxush hodisalar va miya metastazlari kabi klinik muammolarni hal qilish uchun mo'ljallangan yangi ROS1-selektiv inhibitor; Neladalkib (NVL-655), birinchi, ikkinchi va uchinchi avlod ALK inhibitorlaridan foydalanishni cheklashi mumkin bo'lgan davolanishga chidamlilikning paydo bo'lishi, CNS bilan bog'liq noxush hodisalar va miya metastazlari kabi klinik muammolarni hal qilish uchun mo'ljallangan, miyaga o'tuvchi ALK-selektiv inhibitor, bu ALKOVE-1 klinik sinovining 2-bosqichida; va NVL-330, miyaga o'tuvchi inson epidermis o'sish omilining retseptor 2 (HER2)-selektiv inhibitori, u HER2ex20 bilan bog'liq o'smalarni, miya metastazlarini davolash va tabiiy EGFR ning maqsadli bo'lmagan inhibisyonidan kelib chiqadigan davolashni cheklovchi noxush hodisalardan qochish uchun mo'ljallangan, bu 1a/1b fazali klinik sinovda. Nuvalent, Inc. hamrohlik diagnostikasini ishlab chiqish uchun Guardant Health, Inc. bilan strategik hamkorlikni yo'lga qo'ygan. Kompaniya 2017 yilda tashkil etilgan va uning shtab-kvartirasi Kembrij, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Chelcie Lister | Senior Director of Investor Relations & Corporate Communications |
| Dr. Benjamin Lane Ph.D. | Chief Technical Operations Officer |
| Dr. Christopher D. Turner M.D. | Chief Medical Officer |
| Dr. Henry Pelish Ph.D. | Chief Scientific Officer |
| Dr. James R. Porter Ph.D. | CEO, President & Director |
| Mr. John Soglia Ph.D. | Senior Vice President of Translational Development |
| Mr. Matthew Metivier M.B.A. | Senior Vice President of Human Resources |
| Ms. Alexandra Balcom CPA, M.B.A. | CFO & Treasurer |
| Ms. Darlene Noci | Chief Development Officer |
| Ms. Deborah Ann Miller J.D., Ph.D. | Chief Legal Officer & Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 8-K | nuvl-20260507.htm |
| 2026-05-07 | 10-Q | nuvl-20260331.htm |
| 2026-04-28 | DEFA14A | nuvl-defa14a-2026.htm |
| 2026-04-28 | ARS | nuvl-annual_report-2025.pdf |
| 2026-04-07 | 8-K | nuvl-20260407.htm |
| 2026-02-26 | S-8 | d946720ds8.htm |
| 2026-02-26 | 8-K | nuvl-20260226.htm |
| 2026-01-14 | 8-K | nuvl-20240108.htm |
| 2025-12-22 | S-3ASR | d882069ds3asr.htm |
| 2025-12-16 | 8-K | d53736d8k.htm |